Market closed
Ikena Oncology/$IKNA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ikena Oncology
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Ticker
$IKNA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
14
Website
Ikena Oncology Metrics
BasicAdvanced
$78M
Market cap
-
P/E ratio
-$1.24
EPS
0.49
Beta
-
Dividend rate
Price and volume
Market cap
$78M
Beta
0.49
52-week high
$2.30
52-week low
$1.22
Average daily volume
100K
Financial strength
Current ratio
15.317
Quick ratio
14.939
Long term debt to equity
3.331
Total debt to equity
6.253
Management effectiveness
Return on assets (TTM)
-22.06%
Return on equity (TTM)
-37.08%
Valuation
Price to revenue (TTM)
117.664
Price to book
0.58
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
-1.254
Growth
Revenue change (TTM)
-95.28%
Earnings per share change (TTM)
-23.45%
3-year revenue growth (CAGR)
-60.67%
3-year earnings per share growth (CAGR)
-27.05%
What the Analysts think about Ikena Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ikena Oncology stock.
Ikena Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Ikena Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Ikena Oncology News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ikena Oncology stock?
Ikena Oncology (IKNA) has a market cap of $78M as of December 21, 2024.
What is the P/E ratio for Ikena Oncology stock?
The price to earnings (P/E) ratio for Ikena Oncology (IKNA) stock is 0 as of December 21, 2024.
Does Ikena Oncology stock pay dividends?
No, Ikena Oncology (IKNA) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Ikena Oncology dividend payment date?
Ikena Oncology (IKNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Ikena Oncology?
Ikena Oncology (IKNA) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.